If you see patients with diabetes or obesity, take note. Retatrutide delivered substantial weight loss, A1c drops, and symptom gains in knee osteoarthritis and sleep apnea. Cardiometabolic markers improved, with GI effects and a new UTI signal.

1. Starting With Obesity

Treating obesity can shift many downstream conditions and overall health. Both trials were presented at the ADA Scientific Sessions. The TRANSCEND-T2D-1 study appeared in The Lancet, while TRIUMPH-1 remains unpublished. Both trials also showed meaningful cardiometabolic risk improvements.

2. Diabetes Results Land

Retatrutide lowered A1c by 1.69 to 1.94 percentage points versus 0.81 with placebo. Weight fell 11.5 to 15.3 percent, or 36.6 pounds at the top dose, from a baseline of 96.9 kg. More patients hit standard A1c targets, and experts see it as a new option alongside semaglutide and tirzepatide.

3. Beyond Diabetes Gains

Without diabetes, weight loss reached 28.3 percent (about 70 pounds) at 80 weeks and 30.3 percent (about 85 pounds) by 104 weeks. About two-thirds of participants on the top dose moved below a BMI of 30, including more than a third of those who started with severe obesity. Knee pain scores dropped by up to 73.1%, and sleep apnea severity fell by up to 60.6%.

4. Heart Risk Trends

Markers moved in the right direction in both trials. In TRIUMPH-1, triglycerides fell by up to 41.0%, non-HDL cholesterol by up to 24.2%, systolic blood pressure by up to 12.3 mm Hg, and waist circumference by up to 24.1 cm. Similar trends appeared in the diabetes trial over 40 weeks, with smaller magnitudes (up to 39.6% for triglycerides, 19.8% for non-HDL cholesterol, 6.4 mm Hg for blood pressure, and 12.4 cm for waist circumference).

5. Side Effects and Pace

Expect nausea (up to 42.4% at the top TRIUMPH-1 dose), diarrhea, constipation, and a new UTI signal, mostly in women — up to 8.8% in TRIUMPH-1 and 2.9% in the diabetes trial, versus 0.0%–5.3% with placebo. Most events were mild to moderate and resolved over time, though discontinuations rose with dose, reaching 11.3% at the top obesity-trial dose. Whether rapid weight loss or hydration status drives the UTI signal remains under investigation — a reason to consider a more cautious titration pace and individualized weight-loss goals. 

BOTTOM LINE:

Retatrutide provides substantial weight and A1c reductions with broader health gains. Monitor GI effects and possible UTIs, individualize weight-loss goals, and watch for further data on dosing pace and safety. Ensure patients can access, tolerate, and stay on therapy while longer-term safety data develop.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.